Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Admilparant for idiopathic pulmonary fibrosis
NL-OMON60572Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Admilparant with Placebo (2 arms). Primary endpoint: Absolute change in forced vital capacity. Started Jul 2024; status: active, not recruiting.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON60572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60572.